PDCD1 and pancreatic neoplasm: It is presumable that the addition of anti-CTLA4/anti-PD-1/anti-PDL1 antibody to chemotherapy may be inferior to the combination of targeting molecular in myeloid cells with chemotherapy, especially for resectable pancreatic cancer after surgery in which immunosuppressive myeloid cells’ mobilization into metastatic sites by the host response may overwhelm the highly proliferative tumor cell-killing effect and cytotoxic immune cell recruitment caused by immunogenic cell death.